表达猪细小病毒VP2蛋白的重组猪伪狂犬病毒在小鼠体内的免疫反应

为了研制出能够同时预防猪细小病毒(Porcine parvovirus,PPV)和猪伪狂犬病毒(Pseudorabies virus,PRV)的二联活疫苗,本研究将PPV VP2基因克隆到伪狂犬病毒通用转移质粒pG中,构建重组伪狂犬转移质粒pGVP2。利用脂质体转染法将重组质粒pGVP2和PRV HB98弱毒株DNA共转染至猪睾丸(ST)细胞,使其在ST细胞内发生同源重组,经5次绿色荧光空斑纯化重组病毒rPRV-VP2。分别用重组病毒rPRV-VP2、亲本PRV HB98弱毒株、商品化PPV灭活苗和DMEM细胞培养液免疫6周龄雌性昆明小鼠,2周后进行二免。一免后第7周用PRV强毒NY株对小鼠进行攻毒。结果获得表达VP2基因的重组病毒rPRV-VP2,经ELISA试验、血清中和试验(SN)、血凝抑制试验(HI)和流式细胞检测发现,重组病毒rPRV-VP2株可有效刺激小鼠机体产生抗PPV和PRV抗体,同时具有增强小鼠机体细胞免疫反应的能力,且对PRV强毒攻击具有保护作用。结果表明,重组病毒rPRV-VP2可作为同时预防PPV和PRV感染的重组疫苗候选株。     

猪圆环病毒2型、猪繁殖与呼吸综合征病毒及猪细小病毒混合感染的流行病学调查

根据GenBank上发表的PRRSVORF7、PPVVP2及PCV的基因组序列设计合成引物,建立了分别用于检测PRRSV、PPV和PCV的RT-PCR、PCR及复合PCR方法。应用建立的复合PCR方法对送检的127份病料进行了PCV的检测,对鉴定为PCV2阳性的67份病料再分别进行PRRSV和PPV的检测,以确定猪群中PCV2与PRRSV和,或PPV混合感染情况,结果表明,35份样品表现为PRRSV与PCV2混合感染,占样品总数的52．3％;18份样品表现为PCV2与PPV混合感染,占26．9％。另外,还有一定比例的三重感染,共5个样品,占7．5％。由此可见,猪群中PCV2与PRRSV及PPV混合感染比较普遍。     

疫苗原辅料中猪圆环病毒1型、2型和猪细小病毒PCR检测方法的建立及验证

目的 建立疫苗原辅料中猪圆环病毒1型(porcine circovirus type 1, PCV1)、2型(porcine circovirus type 2, PCV2)和猪细小病毒(porcine parvovirus, PPV)的聚合酶链式反应(polymerase chain reaction, PCR)检测方法并进行验证。方法 根据NCBI公布的PCV1、PCV2和PPV基因序列设计了3对特异性引物,通过优化反应条件,建立起检测疫苗原辅料中PCV1、PCV2和PPV的PCR检测方法,并对方法的重复性、中间精密度、专属性、耐用性和检测限进行了验证。结果 PCR反应的退火温度为55℃,特异性引物浓度为10μmol/L。该方法重复性、中间精密度、专属性和耐用性均良好,对PCV1、PCV2、PPV的最低检测限分别为1 pg/μL、100 fg/μL和10 fg/μL。结论 PCR检测方法可以有效检测出疫苗原辅料中外源病毒污染情况,能为生产合格的疫苗提供质量保证。     

表达猪圆环病毒II型ORF2基因的重组猪伪狂犬病病毒的免疫原性

摘要:【目的】为研制预防猪圆环病毒II型(PCV2)感染的重组伪狂犬病病毒(PRV)活载体疫苗。【方法】将PCV2 ORF2基因插入到PRV通用载体pG中,利用脂质体LipofectamineTM 2000试剂盒将重组转移质粒pGO与猪PRV弱毒HB98株DNA共转染猪睾丸(ST)细胞,通过3轮蚀斑纯化重组病毒。将重组病毒、商品化PCV2灭活苗及DMEM培养液分别免疫6周龄雌性昆明小鼠,4周后加强免疫1次,首免后第8周用PCV2强毒NY株对小鼠进行攻毒。【结果】成功获得表达ORF2基因的重组病毒PGO,首免重组病毒后小 鼠体内抗PCV2的ELISA抗体水平很低,二免后小鼠PCV2特异的ELISA抗体水平明显升高,并且重组病毒组能够激发PCV2特异的淋巴细胞增殖效应。攻毒试验表明重组病毒组和PCV2灭活疫苗组均能有效抵抗PCV2强毒攻击。【结论】表明表达ORF2基因的重组病毒PGO具有良好免疫原性。     

猪圆环病毒2型、猪繁殖与呼吸综合征病毒及猪细小病毒混合感染的流行病学调查

根据GenBank上发表的PRRSV ORF7、PPV VP2及PCV的基因组序列设计合成引物,建立了分别用于检测PRRSV、PPV和PCV的RT-PCR、PCR及复合PCR方法.应用建立的复合PCR方法对送检的127份病料进行了PCV的检测,对鉴定为PCV2阳性的67份病料再分别进行PRRSV和PPV的检测,以确定猪群中PCV2与PRRSV和/或PPV混合感染情况,结果表明,35份样品表现为PRRSV与PCV2混合感染,占样品总数的52.3%;18份样品表现为PCV2与PPV混合感染,占26.9%.另外,还有一定比例的三重感染,共5个样品,占7.5%.由此可见,猪群中PCV2与PRRSV及PPV混合感染比较普遍.     

表达猪圆环病毒Ⅱ型ORF2基因的重组猪伪狂犬病病毒的免疫原性

【目的】为研制预防猪圆环病毒II型(PCV2)感染的重组伪狂犬病病毒(PRV)活载体疫苗。【方法】将PCV2 ORF2基因插入到PRV通用载体pG中,利用脂质体LipofectamineTM2000试剂盒将重组转移质粒pGO与猪PRV弱毒HB98株DNA共转染猪睾丸(ST)细胞,通过3轮蚀斑纯化重组病毒。将重组病毒、商品化PCV2灭活苗及DMEM培养液分别免疫6周龄雌性昆明小鼠,4周后加强免疫1次,首免后第8周用PCV2强毒NY株对小鼠进行攻毒。【结果】成功获得表达ORF2基因的重组病毒PGO,首免重组病毒后小鼠体内抗PCV2的ELISA抗体水平很低,二免后小鼠PCV2特异的ELISA抗体水平明显升高,并且重组病毒组能够激发PCV2特异的淋巴细胞增殖效应。攻毒试验表明重组病毒组和PCV2灭活疫苗组均能有效抵抗PCV2强毒攻击。【结论】表明表达ORF2基因的重组病毒PGO具有良好免疫原性。     

表达猪细小病毒VP2基因的重组伪狂犬病毒的构建及其生物学特征研究

根据Bergeron等报道的猪细小病毒(PPV)基因组,设计一对包含VP2全基因的PCR引物,上下游均引入一个BamHI位点,扩增得到VP2基因后,将其插入到pUSK载体中,构建了转移载体pUSK-VP2.采用脂质体介导的转染方法,将伪狂犬病毒TK-/gG-/LacZ 株的基因组DNA与pUSK-VP2共转染PK-15细胞,待细胞病变后收集病毒液,在空斑纯化的同时,利用检测PPV VP2基因和LacZ基因的PCR方法筛选重组病毒TK-/gG-/VP 2株,Southern blotting、SDS-PAGE、Western blotting和电镜观察鉴定重组病毒,并在不同细胞上测定重组病毒的增殖滴度,接种小鼠进行安全性试验.结果发现,外源基因VP2已成功地插入到TK-/gG-/LacZ 亲本株的基因组中,并获得了表达.表达的VP2蛋白可以与猪细小病毒阳性血清反应,而且可以自行装配成病毒样颗粒.同时发现,VP2基因的插入不影响重组病毒的增殖特性,其毒力与亲本株相当.     

表达猪圆环病毒2型Cap蛋白重组复制缺陷型人5型腺病毒的构建及小鼠免疫试验

构建表达猪圆环病毒2型Cap蛋白重组复制缺陷型人5型腺病毒,评价其对小鼠免疫效果。本研究将编码PCV2Cap蛋白的ORF2克隆到腺病毒表达系统穿梭质粒,构建了重组穿梭质粒pacAd5CMV-Cap。将被限制性内切酶PacI线性化后的骨架质粒和重组穿梭质粒共转染HEK293AD细胞,两者在真核细胞内同源重组并包装出携带PCV2-Cap基因的复制缺陷型重组人5型腺病毒,命名为rAd5-Cap;以同样方法重组获得了不含任何靶基因的野生型重组腺病毒wt-rAd5。病毒增殖稳定后,rAd5-Cap与wt-rAd5滴度可达到108.5 TCID50/mL左右;一步增殖实验证明,相对于wt-rAd5,rAd5-Cap中Cap基因的引入几乎没有给重组腺病毒增殖造成影响。RT-PCR和间接免疫荧光实验显示,rAd5-Cap能够有效介导PCV2Cap蛋白在真核细胞HEK293AD细胞中表达。以107 TCID50的rAd5-Cap肌肉注射接种小鼠,14d后小鼠血清中产生可检测水平的针对Cap蛋白的体液免疫应答,并且至少在免疫后28d之前抗体水平持续加强。对重组腺病毒的分子生物学鉴定和在小鼠上的初步免疫试验结果表明,重组腺病毒rAd5-Cap可介导Cap蛋白在真核细胞中的表达,并且表达的靶蛋白具有较好的免疫原性,为进一步将其开发成新型PCV2疫苗奠定了基础。     

感染性猪圆环病毒2型基因组DNA的分子克隆

本研究通过PCR扩增出猪圆环病毒2型(PCV—2)的全基因组(1768bp),克隆入pcDNA3载体的EcoR I酶切应点,获得含有PCV-2全基因组的重组质粒,命名为pcDNApcv2。将重组质粒大量扩增后,用EcoR I切出1768bp的PCV—2全基因组,在体外用T4DNA连接酶使其连接环化。用脂质体法将体外连接产物转染无PCV污染的PK—15细胞,经4次连续传代,用间接免疫荧光实验(IFA)及电镜观察证实已获得复制能力的PCV—2病毒。由此可见,本试验构建的环化的PCV—2全基因组DNA具有感染性。     

PMWS病猪猪圆环病毒2型全基因组序列分析

根据GenBank中发表的猪圆环病毒2型(PCV2)全基因序列,设计一对特异性引物,用PCR方法直接从5省病料中分别扩增出5个PCV2毒株的全基因组,分别命名为FujianPCV、GuangxiPCV、HainanPCV、HunanPCV和ShandongPCV。将扩增片段克隆于pMD18一T载体,进行序列测定,结果表明,除FujianPCV株核苷酸长度为1768bp,其余四株均为1767bp。应用DNAstar序列分析软件分析表明,本实验的5个PCV2分离株与世界上其它地区的PCV2分离株密切相关,核苷酸序列同源性达93％-98．8％,与PCVl毒株的序列同源性只有68．4％～70％。其中ORFl和ORF2所编码的氨基酸序列与国内外PCV2毒株比较,同源性也很高,分别为98．1％499．4％和88％99．1％。     

A recombinant pseudorabies virus co-expressing capsid proteins precursor P1-2A of FMDV and VP2 protein of porcine parvovirus: a trivalent vaccine candidate

Pseudorabies (PR), foot-and-mouth disease (FMD), and porcine parvovirus disease are three important infectious diseases in swine worldwide. The gene-deleted pseudorabies virus (PRV) has been used as a live-viral vector to develop multivalent genetic engineering vaccine. In this study, a recombinant PRV, which could co-express protein precursor P1-2A of FMDV and VP2 protein of PPV, was constructed using PRV TK⁻/gE⁻/LacZ⁺ mutant as the vector. After homologous recombination and plaque purification, recombinant virus PRV TK⁻/gE⁻/P1-2A-VP2 was acquired and identified. Immunogenicity, safety of the recombinant PRV and its protection against PRV were confirmed in a mouse model by indirect ELISA and serum neutralization test. The results show that the recombinant PRV is a candidate vaccine strain to develop a novel trivalent vaccine against PRV, FMDV and PPV in swine.     

Construction and immunogenicity of recombinant pseudorabies virus expressing the modified GP5m protein of porcine reproduction and respiratory syndrome virus

Pseudorabies virus (PRV),an alpha-herpesvirus,has been developed as a live viral vector for animal vaccines.However,the PRV recombinant virus TK-/gE-/GP5+expressing GP5 of porcine reproductive and respiratory syndrome virus (PRRSV),based on the PRV genetically depleted vaccine strain TK-/gE-/LacZ+,scarcely stimulated the vaccinated animals to produce neutralizing antibodies against PRRSV.To develop a booster-specific immune response of such PRV recombinants,the ORF5m gene (the modified ORF5 gene having better immune responses)was substituted for the ORF5 gene and introduced into PRV TK-/gE-/LacZ+,resulting in a PRV recombinant named TK-/gE-/GPSm+,which expressed the modified GPSm protein.The recombinant virus was confirmed using PCR,Southern blotting and Western blotting.TK-/gE-/GPSm+and TK-/gE-/GP5+expressing the authentic GP5 protein were inoculated into Balb/c mice to evaluate their immune responses.The results indicated that the protecting neutralization antibodies (the 3/6 vaccinated mice obtained 1:16)and cell immune responses induced by TK-/gE-/GPSm+against PRRSV were higher than that induced by TK-/gE-/GP5+.Thus,the development of the new PRV recombinant expressing the modified GP5m protein as a candidate vaccine established the basis for the study of bivalent genetic engineering vaccines against PRRSV and PRV.     

Construction and immunogenicity of recombinant pseudorabies virus expressing the modified GP5m protein of porcine reproduction and respiratory syndrome virus

Pseudorabies virus (PRV), an alpha-herpesvirus, has been developed as a live viral vector for animal vaccines. However, the PRV recombinant virus TK⁻/gE⁻/GP5⁺ expressing GP5 of porcine reproductive and respiratory syndrome virus (PRRSV), based on the PRV genetically depleted vaccine strain TK⁻/gE⁻/LacZ⁺, scarcely stimulated the vaccinated animals to produce neutralizing antibodies against PRRSV. To develop a booster-specific immune response of such PRV recombinants, the ORF5m gene (the modified ORF5 gene having better immune responses) was substituted for the ORF5 gene and introduced into PRV TK⁻/gE⁻/LacZ⁺, resulting in a PRV recombinant named TK⁻/gE⁻/GP5m⁺, which expressed the modified GP5m protein. The recombinant virus was confirmed using PCR, Southern blotting and Western blotting. TK⁻/gE⁻/GP5m⁺ and TK⁻/gE⁻/GP5⁺ expressing the authentic GP5 protein were inoculated into Balb/c mice to evaluate their immune responses. The results indicated that the protecting neutralization antibodies (the 3/6 vaccinated mice obtained 1:16) and cell immune responses induced by TK⁻/gE⁻/GP5m⁺ against PRRSV were higher than that induced by TK⁻/gE⁻/GP5⁺. Thus, the development of the new PRV recombinant expressing the modified GP5m protein as a candidate vaccine established the basis for the study of bivalent genetic engineering vaccines against PRRSV and PRV. Translated from Journal of Biotechnology, 2005, 21(6): 858–864 [译自: 生物工程学报]     

展示生长抑素的猪细小病毒样颗粒构建及其免疫原性

为了获得既可预防猪细小病毒感染又能促进生长的嵌合病毒样颗粒疫苗,以PPV NJ-a株基因组DNA为模板扩增VP2基因片段,在VP2基因N端融合人工合成的4拷贝生长抑素基因,构建杆状病毒转移载体pFast-SS4-VP2。通过转化DH10Bac感受态细胞,pFast-SS4-VP2与穿梭载体Bacmid重组,获得重组Bacmid,命名为rBacmid-SS4-VP2。rBacmid-SS4-VP2转染Sf-9细胞,获得重组病毒rBac-SS4-VP2。SDS-PAGE与Western blotting鉴定可见约68 kDa的rSS4-VP2条带;rBac-SS4-VP2感染细胞IFA检测产生很强的特异性绿色荧光;感染细胞超薄切片电镜观察到大量特征性病毒样颗粒。将重组蛋白分别辅以铝胶、IMS和白油不同佐剂免疫小鼠,通过检测免疫小鼠VP2特异性ELISA抗体、PPV特异性中和抗体、生长抑素的抗体水平及生长激素水平来评价嵌合病毒样颗粒的免疫原性。结果表明,辅以铝胶与IMS佐剂重组蛋白组均产生了与PPV全毒组相似的ELISA抗体与中和抗体反应;重组蛋白免疫组均产生较好的针对生长抑素的抗体反应;免疫小鼠体内生长激素的水平明显升高;其中以铝胶佐剂组产生的各抗体水平最高,白油佐剂组各抗体水平最低。为以后生产安全、有效的颗粒化亚单位疫苗提供了一个新的设计思路,又为应用病毒样颗粒递呈外源肽,从而生产多联亚单位疫苗奠定了基础。     

Coexistence of multiple strains of porcine parvovirus 2 in pig farms

The porcine parvovirus 2 (PPV2) genome was first identified in 2001 in Myanmar. Recently, the PPV2 genome has been found in several other countries. In this study, the prevalence of PPV2 in Japanese domestic pigs was investigated and found to be 58% (69/120) in healthy domestic pigs and 100% (69/69) in sick domestic pigs. Sequencing and phylogenetic analysis of the PCR products of the VP1 gene and an almost full length PPV2 clone indicated that diverged PPV2 strains exist in Japan. Clearly distinct strains of PPV2 were detected in 7 of the 10 pig farms.     

Enhancement of the immunogenicity of a porcine circovirus type 2 DNA vaccine by a recombinant plasmid coexpressing capsid protein and porcine interleukin‐6 in mice

The development of effective vaccines against porcine circovirus type 2 (PCV2) has been accepted as an important strategy in the prophylaxis of post‐weaning multisystemic wasting syndrome; a DNA vaccine expressing the major immunogenic capsid (Cap) protein of PCV2 is considered to be a promising candidate. However, DNA vaccines usually induce weak immune responses. In this study, it was found that the efficacy of a DNA vaccine expressing Cap protein was improved by simultaneous expression of porcine IL‐6. A plasmid (pIRES‐ORF2/IL6) separately expressing both Cap protein and porcine IL‐6 was constructed and compared with another plasmid (pIRES‐ORF2) expressing Cap protein for its potential to induce PCV2‐specific immune responses. Mice were vaccinated i.m. twice at 3 week intervals and the induced humoral and cellular responses evaluated. All animals vaccinated with pIRES‐ORF2/IL6 and pIRES‐ORF2 developed specific anti‐PCV2 antibodies (according to enzyme‐linked immunosorbent assay) and a T lymphocyte proliferation response. The percentages of CD3⁺, CD3⁺CD8⁺, and CD3⁺CD4⁺ subgroups of peripheral blood T‐lymphocytes were significantly higher in mice immunized with pIRES‐ORF2/IL6 than in those that had received pIRES‐ORF2. After challenge with the virulent PCV2 Wuzhi isolate, mice vaccinated with pIRES‐ORF2/IL6 had significantly less viral replication than those vaccinated with pIRES‐ORF2, suggesting that the protective immunity induced by pIRES‐ORF2/IL6 is superior to that induced by pIRES‐ORF2.     

Production of porcine parvovirus virus-like particles using silkworm larvae

Porcine parvovirus (PPV) is a significant causative agent of porcine reproductive failure, causing serious economic losses in the swine industry. PPV is a nonenveloped virus, and its capsid is assembled from three viral proteins (VP1, VP2, and VP3). The major capsid protein, VP2, is the main target for PPV neutralizing antibodies and vaccine development. In this study, PPV-VP2 protein was expressed in silkworm larvae, and its antigenicity and production were compared with those in B. mori cells (Bm5). The recombinant VP2 protein was expressed successfully in silkworm larvae and Bm5 cells with a size of approximately 64 kDa. The formation of virus-like particles (VLPs) by recombinant PPV-VP2 was confirmed through transmission electron microscopy. The recombinant PPV-VP2 protein assembled into spherical particles with diameters ranging from 20 to 22 nm. The antigenicity of PPV-VLPs was comparatively analyzed between Bm5 cells and silkworm larvae by ELISA, hemagglutination and hemagglutination inhibition assays. Consequently, it was confirmed that the PPV-VLPs produced in the silkworm larvae were more antigenic than VLPs produced in Bm5 cells. Therefore, it is expected that economical and effective vaccine development will be possible by mass production of PPV-VLPs in silkworm larvae.     

An experimental live chimeric porcine circovirus 1-2a vaccine decreases porcine circovirus 2b viremia when administered intramuscularly or orally in a porcine circovirus 2b and porcine reproductive and respiratory syndrome virus dual-challenge model

Commercially available inactivated vaccines against porcine circovirus type 2 (PCV2) have been shown to be effective in reducing PCV2 viremia. Live-attenuated, orally administered vaccines are widely used in the swine industry for several pathogens because of their ease of use yet they are not currently available for PCV2 and efficacy. The aims of this study were to determine the efficacy of a live-attenuated chimeric PCV2 vaccine in a dual-challenge model using PCV2b and porcine reproductive and respiratory syndrome virus (PRRSV) and to compare intramuscular (IM) and oral (PO) routes of vaccination. Eighty-three 2-week-old pigs were randomized into 12 treatment groups: four vaccinated IM, four vaccinated PO and four non-vaccinated (control) groups. Vaccination was performed at 3 weeks of age using a PCV1-2a live-attenuated vaccine followed by no challenge, or challenge with PCV2b, PRRSV or a combination of PCV2b and PRRSV at 7 weeks of age. IM administration of the vaccine elicited an anti-PCV2 antibody response between 14 and 28 days post vaccination, 21/28 of the pigs being seropositive prior to challenge. In contrast, the anti-PCV2 antibody response in PO vaccinated pigs was delayed, only 1/27 of the pigs being seropositive at challenge. At 21 days post challenge, PCV2 DNA loads were reduced by 80.4% in the IM vaccinated groups and by 29.6% in the PO vaccinated groups. PCV1-2a (vaccine) viremia was not identified in any of the pigs. Under the conditions of this study, the live attenuated PCV1-2a vaccine was safe and provided immune protection resulting in reduction of viremia. The IM route provided the most effective protection.     

共表达PCV2 ORF2和猪IL-18基因的重组猪伪狂犬病毒对小鼠的免疫原性

【目的】研制猪伪狂犬病毒(PRV)和猪圆环病毒2型(PCV2)的二联活疫苗,并用猪IL-18作为免疫佐剂。【方法】将猪IL-18基因插入到质粒p GO中,获得的重组转移质粒p GO18与猪PRV弱毒HB98株DNA共转染ST细胞,并进行空斑筛选和纯化;RT-PCR和Western blot分别从转录和蛋白水平鉴定其表达情况。将重组病毒PGO18和PGO、PRV弱毒株HB98、PCV2灭活商品苗和1640细胞培养基分别免疫6周龄雌性昆明小鼠,4周后二次免疫,二免后4周用PCV2 DF强毒和PRV Min/A强毒接种小鼠。通过ELISA、血清中和试验和流式细胞术及攻毒保护试验评价重组病毒的免疫原性。【结果】获得了重组病毒PGO18,并且可在ST细胞内表达;PGO18可诱导小鼠机体产生PCV2的ELISA和PRV的中和抗体水平,刺激CD3+、CD4+、CD8+T细胞亚群的增殖,且能有效抵抗PCV2和PRV强毒攻击。【结论】IL-18基因可增强重组病毒的免疫效果,使重组病毒具有良好的免疫原性,有望成为防治PCV2和PRV的候选疫苗株。     

表达猪繁殖与呼吸综合征病毒GP5和M融合蛋白的重组腺病毒的构建及其对小鼠的免疫原性

利用口蹄疫病毒(FMDV)2A蛋白具有自我裂解的功能,将其作为连接肽将猪繁殖与呼吸综合征病毒(PRRSV)的GP5和M蛋白编码基因串联,置于复制缺陷型腺病毒载体的表达盒中,通过一次转录和翻译,可以同时实现2个蛋白的表达,以发挥GP5蛋白的病毒中和优势和M蛋白的细胞免疫优势作用。分别利用RT-PCR、间接免疫荧光和Western blotting等方法,对获得的重组腺病毒(rAd-GP5-2A-M)进行检测,结果均证明GP5-2A-M蛋白不仅获得了正确表达,而且能自我裂解为GP5和M蛋白。以单独表达GP5(rAd-GP5)、M(rAd-M)和融合表达GP5-M(rAd-GP5-M)的重组腺病毒为对照,研究该重组腺病毒在小鼠体内诱导免疫应答情况,结果表明,虽然4种重组腺病毒均能诱导小鼠产生特异性抗体和细胞免疫反应,但重组腺病毒rAd-GP5-2A-M所诱导产生的体液免疫和细胞免疫应答水平最高。本研究结果提示,利用具有自动裂解功能的FMDV2A多肽构建PRRSV复合基因工程疫苗是一种切实可行的新策略,也为构建其他动物病毒病的基因工程疫苗提供了新思路。